Management Board discusses EMA’s future temporary and permanent premises in Amsterdam

The European Medicines Agency (EMA) Management Board has met to discuss the EMA’s future temporary and permanent premises in Amsterdam. The United Kingdom (UK) withdraws from the European Union (EU) in March 2019, thus the EMA will move from London to Amsterdam before this date. Completely new, tailor-made EMA premises are being built by the Dutch authorities in the district Zuidas. However, the building will not be completed by 30th March 2019, therefore the availability of a temporary building was part of the Netherland’s bid to host the Agency.

Good progress has been made regarding the temporary premises, which are located in the Sloterdijk area of Amsterdam. It has been confirmed that the Spark building will be made available on 1st January 2019, and be refurbished by the Dutch authorities in accordance with EMA’s requirements. The aim is for the new permanent building to be completed on 15th November 2019.

During the meeting the Board discussed critical elements of the dossier to be submitted to the Budgetary Authority and asked for additional information in order to progress the notification procedure in the shortest possible timeframe. Notification of EMA’s intention to move from the temporary to the permanent building is required by the EMA’s financial regulation and is a building block of the approval process. “EMA can only enter into a contractual obligation for its new final premises on the basis of a positive opinion from the Budgetary Authority.”

To read more about the EMA Management Board meeting to build the approval process of EMA premises in Amsterdam, please click here.